Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen

T Tim Bognàr ¹, J S Jurjen Kingma ^2 3, E H Erin Smeijsters ², K C M Kim van der Elst ², C T M Klaartje de Kanter ⁴, C A Caroline Lindemans ^5 6, A C G Toine Egberts ^2 7, I H Imke Bartelink ^# 8 9, A Arief Lalmohamed ^# 2 7

Affiliations Expand

• PMID: 37002411

• DOI: 10.1038/s41409-023-01971-z

Abstract

Busulfan exposure has previously been linked to clinical outcomes, hence the need for therapeutic drug monitoring (TDM). Study objective was to evaluate the effect of day 1 TDM-guided dosing (regimen d1) versus days 1 + 2 TDM-guided dosing (regimen d1 + 2) on attaining adequate busulfan exposure. In this observational study, we included all children receiving busulfan-based allogeneic hematopoietic cell transplantation. Primary outcome was the percentage of patients achieving busulfan target attainment in both TDM regimens. Secondary outcomes were the variance in busulfan exposure and day-4 clearance (Cl_day4) estimates between both TDM regimens and dosing day 1 and 2. In regimen d1, 84.3% (n = 91/108) attained a therapeutic busulfan exposure, while in regimen d1 + 2 a proportion of 90.9% was found (n = 30/33, not-significant). Variance of Cl_day4 estimate based on busulfan day 2 concentrations was significantly smaller than the variance of Cl_day4 estimates based on day 1 concentrations (p < 0.001). Therefore, day 1-guided TDM (pharmacometric model-based) of busulfan may be sufficient for attaining optimal target exposure, provided that subsequent TDM is carried out if required. However, performing TDM on subsequent days may be beneficial, as measurements on day 2 seemed to reduce the variance in the estimated clearance as compared to day 1 sampling.

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

PubMed Disclaimer

Similar articles

• Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.

  Bognàr T, Bartelink IH, Egberts TCG, Rademaker CMA, Versluys AB, Slatter MA, Kletzel M, Nath CE, Cuvelier GDE, Savic RM, Dvorak C, Long-Boyle JR, Cowan MJ, Bittencourt H, Bredius RGM, Güngör T, Shaw PJ, Ansari M, Hassan M, Krajinovic M, Hempel G, Marktel S, Chiesa R, Théoret Y, Lund T, Orchard PJ, Wynn RF, Boelens JJ, Lalmohamed A.Transplant Cell Ther. 2022 Apr;28(4):196-202. doi: 10.1016/j.jtct.2022.01.013. Epub 2022 Jan 19.PMID: 35065280

• Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients.

  Salman B, Al-Za'abi M, Al-Huneini M, Dennison D, Al-Rawas A, Al-Kindi S, Al-Farsi K, Tauro M, Al-Khabori M.Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):70-78. doi: 10.1016/j.hemonc.2017.03.003. Epub 2017 Apr 6.PMID: 28408108

• Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.

  Shukla P, Dvorak CC, Long-Boyle J, Kharbanda S.Int J Mol Sci. 2020 Aug 6;21(16):5634. doi: 10.3390/ijms21165634.PMID: 32781600Free PMC article.

• Therapeutic drug monitoring of busulfan in transplantation.

  Russell JA, Kangarloo SB.Curr Pharm Des. 2008;14(20):1936-49. doi: 10.2174/138161208785061382.PMID: 18691105Review.

• Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions.

  Combarel D, Tran J, Delahousse J, Vassal G, Paci A.Expert Opin Drug Metab Toxicol. 2023 Feb;19(2):75-90. doi: 10.1080/17425255.2023.2192924. Epub 2023 Mar 29.PMID: 36939456Review.

See all similar articles

Cited by

• Therapeutic Drug Monitoring of Antimicrobial Drugs in Children with Cancer: A New Tool for Personalized Medicine.

  Masetti R, Bossù G, Muratore E, Leardini D, Gatti M, Di Sario R, Pea F, Esposito S.Paediatr Drugs. 2025 Jan;27(1):41-56. doi: 10.1007/s40272-024-00663-5. Epub 2024 Nov 6.PMID: 39503988Review.

• Model-Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations.

  Mahomedradja RF, Bognàr T, van Schie KE, Kuipers IT, de Witte MA, Kuball JHE, Nur E, Wilhelm BJ, Heerma van Voss MR, Franken L, Lalmohamed A, Swart ENL, de Leeuw DC, Bartelink IH.Clin Pharmacol Ther. 2025 Sep;118(3):723-734. doi: 10.1002/cpt.3748. Epub 2025 Jun 22.PMID: 40545743Free PMC article.

• Updated EBMT/ESID inborn errors working party guidelines for haematopoietic stem cell transplantation for inborn errors of immunity and metabolism.

  Albert MH, Lankester AC, Wynn R, Gennery AR, Hoenig M, Kreins A, Morris EC, Slatter M, Bernardo ME, Neven B; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation and the European Society for Immune Deficiencies, and the European Reference Network on Rare Primary Immunodeficiency Autoinflammatory Autoimmune diseases (RITA).Bone Marrow Transplant. 2026 Jul;61(7):791-804. doi: 10.1038/s41409-026-02906-0. Epub 2026 May 22.PMID: 42174044Free PMC article.Review.No abstract available.

• Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients.

  Ben Hassine K, Daali Y, Gloor Y, Nava T, Théorêt Y, Krajinovic M, Bittencourt H, Satyanarayana Uppugunduri CR, Ansari M.Ther Drug Monit. 2024 Dec 1;46(6):786-796. doi: 10.1097/FTD.0000000000001217. Epub 2024 Jun 14.PMID: 38885146Free PMC article.

• Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial.

  Yamaguchi A, Hirabayashi S, Niki K, Kagami K, Terashita Y, Cho Y, Manabe A, Sugawara M, Takekuma Y.Int J Hematol. 2025 Feb;121(2):244-251. doi: 10.1007/s12185-024-03891-0. Epub 2024 Dec 3.PMID: 39625679

References

1. Bartelink IH, Lalmohamed A, van Reij EML, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:526–36. - DOI

2. Bognàr T, Bartelink IH, Egberts TCG, Rademaker CMA, Versluys AB, Slatter MA, et al. Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation. Transpl Cell Ther. 2022;28:196–202. - DOI

3. Ruutu T, van der Werf S, van Biezen A, Backman JT, Peczynski C, Kröger N, et al. Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. Bone Marrow Transpl. 2019;54:2013–9. - DOI

4. Lawson R, Staatz CE, Fraser CJ, Hennig S. Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin Pharmacokinet. 2021;60:17–51. - DOI - PubMed

5. Marsit H, Philippe M, Neely M, Rushing T, Bertrand Y, Ducher M, et al. Intra-individual pharmacokinetic variability of intravenous busulfan in hematopoietic stem cell-transplanted children. Clin Pharmacokinet. 2020;59:1049–61. - DOI - PubMed

Show all 28 references